Your browser is no longer supported. Please, upgrade your browser.
Settings
BYSI [NASD]
BeyondSpring Inc.
Index- P/E- EPS (ttm)-2.04 Insider Own71.61% Shs Outstand33.96M Perf Week6.82%
Market Cap444.63M Forward P/E- EPS next Y-1.79 Insider Trans0.00% Shs Float11.10M Perf Month13.62%
Income-61.00M PEG- EPS next Q-0.54 Inst Own19.30% Short Float11.97% Perf Quarter-10.84%
Sales0.20M P/S2223.14 EPS this Y-31.60% Inst Trans14.70% Short Ratio7.08 Perf Half Y7.63%
Book/sh2.60 P/B4.40 EPS next Y20.40% ROA-103.10% Target Price- Perf Year-30.22%
Cash/sh2.81 P/C4.06 EPS next 5Y- ROE-150.40% 52W Range9.24 - 21.50 Perf YTD-6.31%
Dividend- P/FCF- EPS past 5Y-31.10% ROI-71.00% 52W High-45.77% Beta0.53
Dividend %- Quick Ratio8.20 Sales past 5Y- Gross Margin- 52W Low26.19% ATR0.68
Employees91 Current Ratio8.20 Sales Q/Q- Oper. Margin- RSI (14)58.90 Volatility6.84% 6.05%
OptionableYes Debt/Eq0.02 EPS Q/Q0.10% Profit Margin- Rel Volume0.23 Prev Close11.43
ShortableYes LT Debt/Eq0.02 EarningsJun 16 BMO Payout- Avg Volume187.71K Price11.66
Recom1.60 SMA209.03% SMA5012.26% SMA200-5.88% Volume17,044 Change2.01%
Apr-05-21Downgrade H.C. Wainwright Buy → Neutral
Jan-11-21Initiated BofA Securities Buy $25
Dec-29-20Initiated Evercore ISI Outperform $30
Feb-07-20Initiated Jefferies Buy $25
Jan-10-20Initiated Nomura Buy $34
Dec-03-19Initiated William Blair Outperform
Jul-10-19Reiterated H.C. Wainwright Buy $60 → $41
Apr-30-19Downgrade Maxim Group Buy → Hold
Oct-25-18Reiterated Maxim Group Buy $48 → $35
Jun-11-21 08:00AM  
Jun-10-21 07:00AM  
Jun-08-21 07:00AM  
Jun-07-21 07:00AM  
Jun-04-21 07:00AM  
Jun-01-21 07:00AM  
May-26-21 04:05PM  
May-24-21 07:30AM  
May-10-21 08:18AM  
Apr-30-21 06:01PM  
08:00AM  
07:00AM  
Apr-28-21 04:37PM  
Apr-27-21 11:22AM  
Apr-01-21 07:11AM  
Mar-31-21 11:21PM  
Mar-21-21 04:14AM  
Mar-11-21 04:01PM  
Jan-11-21 10:06AM  
Dec-29-20 03:27PM  
09:19AM  
08:00AM  
Dec-17-20 08:00AM  
Dec-10-20 08:00AM  
Nov-29-20 09:45AM  
Nov-24-20 08:59PM  
Nov-23-20 04:01PM  
Nov-19-20 08:00AM  
Nov-17-20 04:01PM  
08:00AM  
Nov-16-20 07:00AM  
Nov-13-20 04:46PM  
07:00AM  
Oct-14-20 07:00AM  
Oct-12-20 07:00AM  
Sep-29-20 08:00AM  
Sep-24-20 08:00AM  
Sep-22-20 08:30AM  
07:43AM  
Sep-11-20 08:00AM  
Sep-10-20 08:37AM  
Sep-08-20 07:00AM  
Sep-03-20 03:30PM  
07:00AM  
Aug-27-20 08:00AM  
Aug-18-20 08:00AM  
Aug-11-20 08:00AM  
Jun-30-20 07:00AM  
Jun-24-20 12:02AM  
Jun-23-20 08:00AM  
Jun-19-20 05:32AM  
Jun-18-20 04:06PM  
Jun-15-20 07:00AM  
Jun-11-20 08:00AM  
Jun-09-20 08:00AM  
Jun-03-20 08:00AM  
Jun-02-20 08:00AM  
May-13-20 08:00AM  
May-01-20 08:00AM  
Apr-30-20 05:05PM  
07:00AM  
Apr-29-20 08:00AM  
Apr-23-20 08:00AM  
Mar-30-20 08:00AM  
Mar-26-20 11:06AM  
Mar-23-20 09:00AM  
Mar-11-20 08:00AM  
Feb-10-20 08:00AM  
Jan-23-20 08:00AM  
Jan-06-20 08:00AM  
Dec-19-19 08:00AM  
Dec-18-19 07:00AM  
Dec-11-19 09:01AM  
Dec-10-19 08:02AM  
Dec-09-19 08:01AM  
Nov-11-19 08:00AM  
Nov-06-19 08:05AM  
Oct-25-19 09:01AM  
Oct-24-19 04:03PM  
Oct-23-19 08:00AM  
Oct-17-19 08:00AM  
Oct-08-19 08:00AM  
Oct-01-19 08:00AM  
Sep-26-19 12:39PM  
Sep-23-19 08:00AM  
Sep-18-19 07:00AM  
06:00AM  
Sep-11-19 08:00AM  
Sep-10-19 08:00AM  
Sep-06-19 07:00AM  
Aug-23-19 08:00AM  
Jul-17-19 09:05AM  
Jul-16-19 04:07PM  
Jul-10-19 08:23AM  
Jun-28-19 02:19PM  
Jun-20-19 08:00AM  
Jun-04-19 08:00AM  
May-20-19 08:03AM  
May-16-19 08:01AM  
Apr-30-19 04:15PM  
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.